Chief Executive Officer
HIGHLIGHTS FOR THE QUARTER
Last year’s comparative figures are presented in brackets.
Financial highlights
Business highlights
DOWNLOAD
Download the full report for Q2 2023/34 and the half-year here
Q2 2023/24 CONFERENCE CALL
A conference call is broadcast live today, Tuesday 14 May 2024, at 11:00 (CET), via ambu.com/webcastQ22024. To ask questions during the Q&A session, please register prior to the call via ambu.com/conferencecallQ22024register. Upon registration, you will receive an e-mail with information to access the call.
The presentation can be downloaded at Ambu.com/presentations
19
Apr. 2024
add Details
Today, Ambu announces 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) of its new generation duodenoscopy solution, Ambu® aScope™ Duodeno 2 and Ambu® aBox™ 2, for use in ERCP1 procedures.
In the development of the new generation solution, Ambu has worked closely with a range of experienced gastroenterology professionals and ERCP specialists to rethink its duodenoscopy solution, with a clear focus on enhancing critical performance factors and enabling integration with the aBox™ 2 endoscopy system.
"I am impressed with the improvements in the new aScope Duodeno 2, and I believe that it holds potential for ERCP in the future. Ambu has clearly taken the customer feedback into the development of this new duodenoscope. I highly valued the collaboration throughout the development phase, and I am looking forward to continuing to engage with Ambu on future innovations."
ABHITABH PATIL, M.D.2
Interventional Gastroenterology
President of Florida Gastroenterologic Society
St. Petersburg, FL, USA
PROVIDING FLEXIBILITY AND STERILITY WITH PATIENT-READY DUODENOSCOPES
The new generation aScope™ Duodeno 2 solution is designed to meet the high-performance expectations in ERCP and furthermore relieve the burden of complex and time-consuming reprocessing conducted today. As aScope™ Duodeno 2 is 100% sterile, the solution enables physicians and hospital systems to adhere to the safety recommendations issued by the FDA3 in 2019 and 2022, urging U.S. hospitals and endoscopy facilities to transition to duodenoscopes that are partially or completely single-use.
Furthermore, given the often long and physically demanding nature of ERCP procedures, the handle of Ambu’s new generation aScope Duodeno 2 solution aims to alleviate strain on endoscopists through improved ergonomics. In addition, Ambu is planning to include bioplastic materials in the handle of the new generation solution over time – materials that are derived from a mix of fossil-based and second-generation bio-based feedstock, e.g., recycled food waste, ensuring a raw material with a lower carbon footprint.
"Our new generation duodenoscope solution is a result of a close partnership with gastroenterologists. Based on their feedback, we have developed a solution to meet the distinct procedural needs in ERCP. We are dedicated to continuing Ambu’s focused journey within GI, anchored in profound customer understanding as a pivotal driver for unlocking long-term potential – for gastroenterologists, patients and Ambu."
BRITT MEELBY JENSEN
Chief Executive Officer, Ambu
Ambu will conduct an extended controlled market release with key hospitals to evaluate the clinical performance in a real-life setting. The solution will be available in the market from 2024/25, and the FDA clearance will therefore not change the financial guidance for 2023/24.
----------------------------------------------------------------------------------------------
10
Apr. 2024
add Details
Today, Ambu announces preliminary results for the first half-year of 2023/24 and adjusts its expectations for the full financial year 2023/24. As a result of solid financial performance year-to-date and expected continued momentum in revenue growth, Ambu increases its financial outlook for organic revenue growth to 10-12% (previously 7-10%) and for EBIT margin before special items to 10-12% (previously 8-10%).
In addition, the company raises its free cash flow expectations to DKK +370m (previously DKK +270m).
The raised outlook is mainly driven by better-than-expected outcomes of contract negotiations in Anaesthesia & Patient Monitoring, strong organic growth in Endoscopy Solutions and continued strengthened operational leverage.
PRELIMINARY AND UNAUDITED FINANCIAL HIGHLIGHTS FOR Q2 2023/24
Last year’s comparative figures are stated in brackets.
REVISED OUTLOOK FOR THE FISCAL YEAR 2023/24
Driven by the development in the first half of the 2023/24 financial year, Ambu’s 2023/24 financial outlook is set as per below:
OUTLOOK FY 2023/24 | 10 APRIL 2024 | PREVIOUSLY |
Organic revenue growth | 10-12% | 7-10% |
EBIT margin before special items | 10-12% | 8-10% |
In addition, Ambu’s free cash flow expectations are set for DKK +370m (previously DKK +270m), while the expectation for Endoscopy Solutions organic revenue growth is maintained at ~15%.
Ambu will publish its full Q2 and half-year 2023/24 interim results, as previously announced, on 14 May 2024.
View the PDF version of the company announcement here.
30
Aug. 2024
30
Sep. 2024
05
Nov. 2024